Literature DB >> 17077321

Evidence for the multimeric structure of ferroportin.

Ivana De Domenico1, Diane McVey Ward, Giovanni Musci, Jerry Kaplan.   

Abstract

Ferroportin (Fpn) (IREG1, SLC40A1, MTP1) is an iron transporter, and mutations in Fpn result in a genetically dominant form of iron overload disease. Previously, we demonstrated that Fpn is a multimer and that mutations in Fpn are dominant negative. Other studies have suggested that Fpn is not a multimer and that overexpression or epitope tags might affect the localization, topology, or multimerization of Fpn. We generated wild-type Fpn with 3 different epitopes, GFP, FLAG, and c-myc, and expressed these constructs in cultured cells. Co-expression of any 2 different epitope-tagged proteins in the same cell resulted in their quantitative coimmunoprecipitation. Treatment of Fpn-GFP/Fpn-FLAG-expressing cells with crosslinking reagents resulted in the crosslinking of Fpn-GFP and Fpn-FLAG. Western analysis of rat glioma C6 cells or mouse bone marrow macrophages exposed to crosslinking reagents showed that endogenous Fpn is a dimer. These results support the hypothesis that the dominant inheritance of Fpn-iron overload disease is due to the dominant-negative effects of mutant Fpn proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17077321      PMCID: PMC1801059          DOI: 10.1182/blood-2006-06-032516

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  The molecular basis of ferroportin-linked hemochromatosis.

Authors:  Ivana De Domenico; Diane McVey Ward; Elizabeta Nemeth; Michael B Vaughn; Giovanni Musci; Tomas Ganz; Jerry Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-13       Impact factor: 11.205

2.  Hemochromatosis with mutation of the ferroportin 1 (IREG1) gene.

Authors:  Weidong Liu; Souji Shimomura; Hiroyasu Imanishi; Yuna Iwamoto; Naoto Ikeda; Masaki Saito; Masao Ohno; Naoki Hara; Tetsuo Yamamoto; Hideji Nakamura; Toshikazu Hada
Journal:  Intern Med       Date:  2005-04       Impact factor: 1.271

3.  Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.

Authors:  Elizabeta Nemeth; Marie S Tuttle; Julie Powelson; Michael B Vaughn; Adriana Donovan; Diane McVey Ward; Tomas Ganz; Jerry Kaplan
Journal:  Science       Date:  2004-10-28       Impact factor: 47.728

4.  In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.

Authors:  Lisa M Schimanski; Hal Drakesmith; Alison T Merryweather-Clarke; Vip Viprakasit; Jon P Edwards; Emma Sweetland; Judy M Bastin; Diana Cowley; Yingyong Chinthammitr; Kathryn J H Robson; Alain R M Townsend
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

5.  Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation.

Authors:  Funmei Yang; Xiao-Bing Liu; Marlon Quinones; Peter C Melby; Andrew Ghio; David J Haile
Journal:  J Biol Chem       Date:  2002-08-02       Impact factor: 5.157

6.  Disruption of ferroportin 1 regulation causes dynamic alterations in iron homeostasis and erythropoiesis in polycythaemia mice.

Authors:  Henry Mok; Jaroslav Jelinek; Sonia Pai; Bruce M Cattanach; Josef T Prchal; Hagop Youssoufian; Armin Schumacher
Journal:  Development       Date:  2004-04       Impact factor: 6.868

Review 7.  Balancing acts: molecular control of mammalian iron metabolism.

Authors:  Matthias W Hentze; Martina U Muckenthaler; Nancy C Andrews
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

8.  Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system.

Authors:  Suh Young Jeong; Samuel David
Journal:  J Biol Chem       Date:  2003-05-12       Impact factor: 5.157

Review 9.  The ferroportin disease.

Authors:  Antonello Pietrangelo
Journal:  Blood Cells Mol Dis       Date:  2004 Jan-Feb       Impact factor: 3.039

10.  Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene.

Authors:  G Montosi; A Donovan; A Totaro; C Garuti; E Pignatti; S Cassanelli; C C Trenor; P Gasparini; N C Andrews; A Pietrangelo
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

View more
  28 in total

Review 1.  Ferroportin-mediated iron transport: expression and regulation.

Authors:  Diane M Ward; Jerry Kaplan
Journal:  Biochim Biophys Acta       Date:  2012-03-13

2.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 3.  Hepcidin and iron regulation, 10 years later.

Authors:  Tomas Ganz
Journal:  Blood       Date:  2011-02-23       Impact factor: 22.113

Review 4.  Ceruloplasmin-ferroportin system of iron traffic in vertebrates.

Authors:  Giovanni Musci; Fabio Polticelli; Maria Carmela Bonaccorsi di Patti
Journal:  World J Biol Chem       Date:  2014-05-26

5.  Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2.

Authors:  Ivana De Domenico; Eric Lo; Diane M Ward; Jerry Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

6.  The molecular mechanism of hepcidin-mediated ferroportin down-regulation.

Authors:  Ivana De Domenico; Diane McVey Ward; Charles Langelier; Michael B Vaughn; Elizabeta Nemeth; Wesley I Sundquist; Tomas Ganz; Giovanni Musci; Jerry Kaplan
Journal:  Mol Biol Cell       Date:  2007-05-02       Impact factor: 4.138

Review 7.  Regulation of iron absorption in hemoglobinopathies.

Authors:  Gideon Rechavi; Stefano Rivella
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

8.  Ferroportin and erythroid cells: an update.

Authors:  Luciano Cianetti; Marco Gabbianelli; Nadia Maria Sposi
Journal:  Adv Hematol       Date:  2010-08-11

9.  The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease.

Authors:  Irene E Zohn; Ivana De Domenico; Andrew Pollock; Diane McVey Ward; Jessica F Goodman; Xiayun Liang; Amaru J Sanchez; Lee Niswander; Jerry Kaplan
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113

10.  Manganese efflux in Parkinsonism: insights from newly characterized SLC30A10 mutations.

Authors:  Margaret R DeWitt; Pan Chen; Michael Aschner
Journal:  Biochem Biophys Res Commun       Date:  2013-01-26       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.